Project Grant HT9425261E282
Award Date 6/15/26
Completion Date 6/14/29
Dollars Obligated $751K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- Federal Project Grant Award Summary New York University School of Medicine received a $1,346,697 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on June 15, 2026, with an ultimate completion date of June 14, 2029. The project, titled "Neoadjuvant Checkpoint and IL-6 Blockade: Mechanisms of Benefit and Toxicity," supports biomedical research investigating immunotherapy approaches in cancer treatment. This...
- Federal Grant Award Summary New York University School of Medicine received a $833,334 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), awarded on September 30, 2026, with performance through September 29, 2029. The award supports research to identify pathways that prevent the emergence of drug-tolerant persisters—a critical area of biomedical investigation relevant to treatment resistance and therapeutic development. This...
- Federal Grant Award Summary New York University School of Medicine received a $2.01M Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research titled "Targeting RAGE After Particulate Matter Exposure: Metabolic Dysregulation and Disease Mitigation," conducted at NYU's location in New York, New York. This research investigates the...
- Federal Project Grant Award Summary New York University received a $791,063 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on September 30, 2025, with completion targeted for September 29, 2029. The award supports the implementation of a formal postvention program designed to serve military mental health clinicians. Postvention programs typically provide crisis intervention, support services, and recovery...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $1,482,860 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded June 1, 2026, with a completion date of May 31, 2029. The award supports research focused on pharmacological targeting of UBR5 for breast cancer immunotherapy, a research initiative aligned with DHA's emphasis on cancer immunotherapy and precision medicine approaches to...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $1,249,920 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded April 1, 2026, with a completion date of March 31, 2029. The award funds research to unravel immunosuppressive mechanisms in breast cancer stem cells for the development of new immunotherapy approaches. This research aligns with the DHA's mission to transform healthcare for...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute For Cancer Research a $533,308 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award funds research titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma," which investigates lymphocyte-activation gene 3 (LAG3) checkpoint inhibition as a therapeutic...
- Federal Grant Award Summary New York University received an $818,929 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on September 30, 2025, with a completion date of September 29, 2029. The grant supports the implementation of a formal postvention program designed to serve military mental health clinicians. Postvention programs typically provide suicide prevention and crisis intervention support following...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Trustees of Columbia University in the City of New York's Health Sciences Division a $1.645 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research on treating HER2 therapy-resistant brain metastasis using antidepressants, conducted at Columbia's Health Sciences Division facility in New York, NY. This project...